With the accelerated approval of Brigatinib, and now three approved ALK inhibitors in the 2nd-line setting, how do you decide between these agents?

A biopsy should be considered for ALK-rearranged lung cancer patients who previously received crizotinib and developed progression whenever safe and feasible. While most patients with acquired resistance to crizotinib will respond to a next-generation agent, and mutational profiling is not strictly ...